Osteoporosis International

, Volume 22, Issue 4, pp 1133–1143 | Cite as

The impact of substance abuse on osteoporosis screening and risk of osteoporosis in women with psychotic disorders

  • D. L. Kelly
  • C. S. Myers
  • M. T. Abrams
  • S. Feldman
  • J. Park
  • R. P. McMahon
  • J.-C. Shim
Original Article



Review of the 1-year prevalence of screening for osteoporosis and of osteoporosis or idiopathic fracture in Maryland Medicaid administrative records found that screening rates did not differ among women in the control population, women with psychosis, and women with major mood disorders, but were reduced compared to controls in women with substance use disorder, with or without psychosis. Prevalence of osteoporosis was increased compared to controls in women with major mood disorders or women over 55 dually diagnosed with psychosis and substance use disorder.


Osteoporosis is a major public health concern. Substance abuse and psychosis may be risk factors, however, frequency of screening and disease risk in women with psychotic disorders and substance use disorder (SUD) remains unknown.


This study examined rates (FY 2005) of osteoporosis screening and disease risk in Medicaid enrolled women aged 50 to 64 (N = 18,953). Four diagnostic groups were characterized: (1) psychosis, (2) SUD, (3) major mood disorder, and (4) controls. The interaction of psychosis and SUD on screening and disease prevalence of osteoporosis was tested.


The prevalence of osteoporosis across the entire population was 6.7%. Four percent of those without an osteoporosis diagnosis received osteoporosis screening with no notable differences between psychosis and controls. Those with SUD, however, had a significant reduction in screening compared to controls (OR = 0.61, 95% CI = 0.40–0.91, p = 0.016). Women with a major mood disorder were more likely to have osteoporosis in their administrative record (OR = 1.32, 95% CI = 1.03–1.70, p = 0.028) compared to controls. Those who were dually diagnosed (SUD and psychosis) in the oldest ages (55–64 years) had a markedly higher prevalence of osteoporosis compared to controls (OR = 6.4 CI = 1.51–27.6, p = 0.012), whereas this interaction (SUD and psychosis) was not significant in the entire population over age 49.


Osteoporosis screening in the Medicaid population is significantly lower for women with SUD, after adjusting for age, race, and Medicaid enrollment category. The prevalence of osteoporosis appears markedly elevated in those with major mood disorders and those over age 55 dually diagnosed with schizophrenia and SUD.


Bone mineral density Medicaid Osteoporosis Psychosis Schizophrenia Screening Substance abuse 



This study was supported by the Intramural Research Program, NIH, National Institute on Drug Abuse and the NIDA Residential Research Support Services Contract HHSN271200599091CADB. The authors wish to thank Cynthia Boddie-Willis, Susan Chen, and Nancy Svehla for their contributions to this work.

Conflicts of interest

Mr. Abrams is a frequent consultant to Maryland's Medicaid Program.


  1. 1.
    Carney CP, Jones L, Woolson RF (2006) Medical comorbidity in women and men with schizophrenia: a population-based controlled study. J Gen Intern Med 21:1133–1137PubMedCrossRefGoogle Scholar
  2. 2.
    Dixon L, Postrado L, Delahanty J, Fischer PJ, Lehman A (1999) The association of medical comorbidity in schizophrenia with poor physical and mental health. J Nerv Ment Dis 187:496–502PubMedCrossRefGoogle Scholar
  3. 3.
    Salloum IM, Douaihy A, Ndimbie OK, Kirisci L (2004) Concurrent alcohol and cocaine dependence impact on physical health among psychiatric patients. J Addict Dis 23:71–81PubMedCrossRefGoogle Scholar
  4. 4.
    Havassy BE, Alvidrez J, Owen KK (2004) Comparisons of patients with comorbid psychiatric and substance use disorders: implications for treatment and service delivery. Am J Psychiatry 161:139–145PubMedCrossRefGoogle Scholar
  5. 5.
    Mackell JA, Harrison DJ, McDonnell DD (2005) Relationship between preventative physical health care and mental health in individuals with schizophrenia: a survey of caregivers. Ment Health Serv Res 7:225–228PubMedCrossRefGoogle Scholar
  6. 6.
    Kelly DL (2006) Treatment considerations in women with schizophrenia. J Womens Health (Larchmt) 15:1132–1140CrossRefGoogle Scholar
  7. 7.
    Kelly DL, Conley RR (2004) Sexuality and schizophrenia: a review. Schizophr Bull 30:767–779PubMedGoogle Scholar
  8. 8.
    Bliuc D, Nguyen ND, Milch VE, Nguyen TV, Eisman JA, Center JR (2009) Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA 301:513–521PubMedCrossRefGoogle Scholar
  9. 9.
    NIH (2001) Consensus conference development panel on osteoporosis prevention, diagnosis, and therapy. JAMA 285:785–795CrossRefGoogle Scholar
  10. 10.
    Thomas PA (2007) Racial and ethnic differences in osteoporosis. J Am Acad Orthop Surg 15(Suppl 1):S26–S30PubMedGoogle Scholar
  11. 11.
    National Osteoporosis Foundation. In. Washington, DCGoogle Scholar
  12. 12.
    O'Keane V (2008) Antipsychotic-induced hyperprolactinaemia, hypogonadism and osteoporosis in the treatment of schizophrenia. J Psychopharmacol 22:70–75PubMedCrossRefGoogle Scholar
  13. 13.
    O'Keane V, Meaney AM (2005) Antipsychotic drugs: a new risk factor for osteoporosis in young women with schizophrenia? J Clin Psychopharmacol 25:26–31PubMedCrossRefGoogle Scholar
  14. 14.
    Jung DU, Conley RR, Kelly DL, Kim DW, Yoon SH, Jang JH, Shin JG, Shim JC (2006) Prevalence of bone mineral density loss in Korean patients with schizophrenia: a cross-sectional study. J Clin Psychiatry 67:1391–1396PubMedCrossRefGoogle Scholar
  15. 15.
    Renn JH, Yang NP, Chueh CM, Lin CY, Lan TH, Chou P (2009) Bone mass in schizophrenia and normal populations across different decades of life. BMC Musculoskelet Disord 10:1PubMedCrossRefGoogle Scholar
  16. 16.
    Meaney AM, O'Keane V (2007) Bone mineral density changes over a year in young females with schizophrenia: relationship to medication and endocrine variables. Schizophr Res 93:136–143PubMedCrossRefGoogle Scholar
  17. 17.
    Shim J, Jung D-U, Oh M, Kong B, Kelly D (2009) Bone mineral density and osteoporosis risk in older patients with schizophrenia: a 3–4 year follow-up study. In International Congress on Schizophrenia Research. San Diego, CAGoogle Scholar
  18. 18.
    Frank RG, Glied S, Carter R (2006) Better but not well: mental health policy in the United States since 1950. Johns Hopkins Univ PrGoogle Scholar
  19. 19.
    Pagano M, Gauvreau K (1993) Principles of biostatistics. Duxbury Press, BelmontGoogle Scholar
  20. 20.
    Studenmund AH (2006) Using econometrics: a practical guide. Addison-WesleyGoogle Scholar
  21. 21.
    Brown SA, Guise TA (2009) Cancer treatment-related bone disease. Crit Rev Eukaryot Gene Expr 19:47–60PubMedGoogle Scholar
  22. 22.
    Bromet EJ, Dew MA, Eaton WW (2002) Epidemiology of psychosis with special reference to schizophrenia. Wiley-Liss, Inc, New YorkGoogle Scholar
  23. 23.
    Adelmann PK (2003) Mental and substance use disorders among Medicaid recipients: prevalence estimates from two national surveys. Adm Policy Ment Health 31:111–129PubMedCrossRefGoogle Scholar
  24. 24.
    Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A (2007) Incidence and economic burden of osteoporosis-related fractures in the United States, 2005–2025. J Bone Miner Res 22:465–475PubMedCrossRefGoogle Scholar
  25. 25.
    Nelson HD, Helfand M, Woolf SH, Allan JD (2002) Screening for postmenopausal osteoporosis: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 137:529–541PubMedGoogle Scholar
  26. 26.
    McBean AM, Yu X (2007) The underuse of screening services among elderly women with diabetes. Diabetes Care 30:1466–1472PubMedCrossRefGoogle Scholar
  27. 27.
    Bishop JR, Alexander B, Lund BC, Klepser TB (2004) Osteoporosis screening and treatment in women with schizophrenia: a controlled study. Pharmacotherapy 24:515–521PubMedCrossRefGoogle Scholar
  28. 28.
    Sampson HW (2002) Alcohol and other factors affecting osteoporosis risk in women. Alcohol Res Health 26:292–298PubMedGoogle Scholar
  29. 29.
    Kim TW, Alford DP, Malabanan A, Holick MF, Samet JH (2006) Low bone density in patients receiving methadone maintenance treatment. Drug Alcohol Depend 85:258–262PubMedCrossRefGoogle Scholar
  30. 30.
    Epstein EE, Fischer-Elber K, Al-Otaiba Z (2007) Women, aging, and alcohol use disorders. J Women Aging 19:31–48PubMedCrossRefGoogle Scholar
  31. 31.
    Lofthus CM, Osnes EK, Meyer HE, Kristiansen IS, Nordsletten L, Falch JA (2006) Young patients with hip fracture: a population-based study of bone mass and risk factors for osteoporosis. Osteoporos Int 17:1666–1672PubMedCrossRefGoogle Scholar
  32. 32.
    Schoenbaum EE, Hartel D, Lo Y, Howard AA, Floris-Moore M, Arnsten JH, Santoro N (2005) HIV infection, drug use, and onset of natural menopause. Clin Infect Dis 41:1517–1524PubMedCrossRefGoogle Scholar
  33. 33.
    Becker D, Liver O, Mester R, Rapoport M, Weizman A, Weiss M (2003) Risperidone, but not olanzapine, decreases bone mineral density in female premenopausal schizophrenia patients. J Clin Psychiatry 64:761–766PubMedCrossRefGoogle Scholar
  34. 34.
    Neuner JM, Zhang X, Sparapani R, Laud PW, Nattinger AB (2007) Racial and socioeconomic disparities in bone density testing before and after hip fracture. J Gen Intern Med 22:1239–1245PubMedCrossRefGoogle Scholar
  35. 35.
    Gourlay ML, Callahan LF, Preisser JS, Sloane PD (2007) Osteoporosis preventive care in white and black women in community family medicine settings. South Med J 100:677–682PubMedGoogle Scholar
  36. 36.
    Pothiwala P, Evans EM, Chapman-Novakofski KM (2006) Ethnic variation in risk for osteoporosis among women: a review of biological and behavioral factors. J Womens Health (Larchmt) 15:709–719CrossRefGoogle Scholar
  37. 37.
    Hochberg MC (2007) Racial differences in bone strength. Trans Am Clin Climatol Assoc 118:305–315PubMedGoogle Scholar
  38. 38.
    Alegria M, Chatterji P, Wells K, Cao Z, Chen CN, Takeuchi D, Jackson J, Meng XL (2008) Disparity in depression treatment among racial and ethnic minority populations in the United States. Psychiatr Serv 59:1264–1272PubMedCrossRefGoogle Scholar
  39. 39.
    Eskandari F, Martinez PE, Torvik S, Phillips TM, Sternberg EM, Mistry S, Ronsaville D, Wesley R, Toomey C, Sebring NG, Reynolds JC, Blackman MR, Calis KA, Gold PW, Cizza G (2007) Low bone mass in premenopausal women with depression. Arch Intern Med 167:2329–2336PubMedCrossRefGoogle Scholar
  40. 40.
    Gold PW, Wong ML, Goldstein DS, Gold HK, Ronsaville DS, Esler M, Alesci S, Masood A, Licinio J, Geracioti TD Jr, Perini G, DeBellis MD, Holmes C, Vgontzas AN, Charney DS, Chrousos GP, McCann SM, Kling MA (2005) Cardiac implications of increased arterial entry and reversible 24-h central and peripheral norepinephrine levels in melancholia. Proc Natl Acad Sci USA 102:8303–8308PubMedCrossRefGoogle Scholar
  41. 41.
    Alesci S, Martinez PE, Kelkar S, Ilias I, Ronsaville DS, Listwak SJ, Ayala AR, Licinio J, Gold HK, Kling MA, Chrousos GP, Gold PW (2005) Major depression is associated with significant diurnal elevations in plasma interleukin-6 levels, a shift of its circadian rhythm, and loss of physiological complexity in its secretion: clinical implications. J Clin Endocrinol Metab 90:2522–2530PubMedCrossRefGoogle Scholar
  42. 42.
    Mezuk B, Eaton WW, Golden SH, Wand G, Lee HB (2008) Depression, antidepressants, and bone mineral density in a population-based cohort. J Gerontol A Biol Sci Med Sci 63:1410–1415PubMedGoogle Scholar
  43. 43.
    RachBeisel J, Scott J, Dixon L (1999) Co-occurring severe mental illness and substance use disorders: a review of recent research. Psychiatr Serv 50:1427–1434PubMedGoogle Scholar
  44. 44.
    Dixon L, Dibietz E, Myers P, Conley R, Medoff D, Lehman AF (1993) Comparison of DSM-III-R diagnoses and a brief interview for substance use among state hospital patients. Hosp Community Psychiatry 44:748–752PubMedGoogle Scholar
  45. 45.
    Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL, Goodwin FK (1990) Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 264:2511–2518PubMedCrossRefGoogle Scholar
  46. 46.
    Kessler RC, Chiu WT, Demler O, Walters EE (2005) Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the national comorbidity survey replication. Arch Gen Psychiatry 62:617–627PubMedCrossRefGoogle Scholar
  47. 47.
    McCreadie RG (2002) Use of drugs, alcohol and tobacco by people with schizophrenia: case-control study. Br J Psychiatry 181:321–325PubMedCrossRefGoogle Scholar
  48. 48.
    Soyka M, Albus M, Kathmann N, Finelli A, Hofstetter S, Holzbach R, Immler B, Sand P (1993) Prevalence of alcohol and drug abuse in schizophrenic inpatients. Eur Arch Psychiatry Clin Neurosci 242:362–372PubMedCrossRefGoogle Scholar
  49. 49.
    Ziedonis DM, Smelson D, Rosenthal RN, Batki SL, Green AI, Henry RJ, Montoya I, Parks J, Weiss RD (2005) Improving the care of individuals with schizophrenia and substance use disorders: consensus recommendations. J Psychiatr Pract 11:315–339PubMedCrossRefGoogle Scholar
  50. 50.
    Green AI, Canuso CM, Brenner MJ, Wojcik JD (2003) Detection and management of comorbidity in patients with schizophrenia. Psychiatr Clin North Am 26:115–139PubMedCrossRefGoogle Scholar

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2010

Authors and Affiliations

  • D. L. Kelly
    • 1
  • C. S. Myers
    • 2
  • M. T. Abrams
    • 3
  • S. Feldman
    • 1
  • J. Park
    • 3
  • R. P. McMahon
    • 1
  • J.-C. Shim
    • 4
  1. 1.Maryland Psychiatric Research CenterUniversity of Maryland School of MedicineBaltimoreUSA
  2. 2.National Institute on Drug Abuse, Intramural Research ProgramBaltimoreUSA
  3. 3.The Hilltop Institute, University of Maryland, Baltimore CountyBaltimoreUSA
  4. 4.Department of Psychiatry and Clinical Trial Center, Busan Paik HospitalInje UniversityBusanSouth Korea

Personalised recommendations